ClinicalTrials.gg
CompletedNCT03267134SUMMITUpdated Jan 14, 2026Results posted

Hydrus Microstent for Refractory Open-Angle Glaucoma

An interventional study of Hydrus Microstent and Ophthalmic surgery in Open-angle Glaucoma, sponsored by Ivantis, Inc.. Completed at 20 sites in 5 countries. Open to participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2026-01-14.

Sponsored by Ivantis, Inc. (part of Alcon) · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
217
Allocation
Not applicable
Ages
45 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 126 studies in Glaucoma, Open-Angle by Alcon — 1 open to participants now, 1 under way, none of them phase 3. Glaucoma, Open-Angle · Alcon.

Enrollment
42nd of 112
217 · median 154
Started
2017
with 4 others
No phase
10 of 126
1 open now
Registered
115th of 126
by date

Among the 126 studies in Glaucoma, Open-Angle by Alcon, this one is the 42nd largest by enrollment of the 112 interventional ones that give a count, is one of 5 that started in 2017, is one of 10 with no phase, and was the 115th registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

1 of the 126 studies in Glaucoma, Open-Angle by Alcon is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 45 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 126 studies in Glaucoma, Open-Angle by Alcon, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety and effectiveness of the Hydrus Microstent in patients with refractory open-angle glaucoma.

Read the detailed description

Participants will attend a screening visit, a baseline visit, a surgery visit, and 8 post-operative visits (Day 1, Day 7, Month 1, Month 2, Month 3, Month 6, Month 9, Month 12), for a total individual duration of approximately 14 months.

03

Conditions studied

  • Open-angle Glaucoma

Keywords

  • Glaucoma
04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Open-angle glaucoma with optic nerve pathology;
  • BCVA of 20/80 or better in study eye;
  • glaucoma;
  • Other protocol-specified inclusion criteria may apply.

Exclusion criteria

Exclusion Criteria:

  • Secondary glaucoma other than pseudoexfoliative and pigmentary glaucoma;
  • Acute angle closure, chronic angle closure, or congenial, malignant, or developmental glaucoma;
  • Pre-perimetric glaucoma;
  • Ocular hypertension
  • Shallow or flat anterior chamber;
  • Other protocol-specified exclusion criteria may apply.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
217 participants (actual)

Study arms

  • Experimental
    Hydrus Microstent

    Hydrus Microstent implanted in the eye per the supplied Hydrus Microstent Instructions for Use and associated training. Only one eye (study eye) will be implanted.

    Device: Hydrus Microstent · Procedure: Ophthalmic surgery

Interventions

  • DeviceHydrus Microstent

    Device implanted into the Schlemm's canal of the eye to provide a natural outflow pathway for aqueous humor, leading to a reduction in intraocular pressure (IOP). The Hydrus Microstent is intended for lifetime use of the glaucoma patient.

  • ProcedureOphthalmic surgery

    Implantation of the Hydrus Microstent performed under either local or topical ophthalmic anesthesia

06

What researchers measure

Primary outcomes

  1. Percentage of Subjects With Greater Than or Equal to a 20 Percent Decrease From Baseline in Mean Diurnal Intraocular Pressure (MDIOP) at Month 12 While Maintaining the Same or Fewer Number of Medications as at Baseline

    Intraocular pressure was measured using Goldmann Applanation tonometry. Three separate IOP measurements were taken over an 8-hour period and averaged together to achieve mean diurnal intraocular pressure.

    Time frame: Baseline, Month 12

Secondary outcomes

  1. Mean Change From Baseline in MDIOP at Month 12

    Intraocular pressure was measured using Goldmann Applanation tonometry and recorded in millimeters mercury (mmHG). Three separate IOP measurements were taken over an 8-hour period and averaged together to achieve mean diurnal intraocular pressure. A negative number represents a reduction from baseline. For non-responders, data was imputed as specified in the protocol. No hypothesis testing was pre-specified for this outcome measure.

    Time frame: Baseline, Month 12

07

Results

Posted Jan 14, 2026

Participant flow

Participants were recruited from 20 investigative sites located in the United States (16), Philippines (1), Spain (1), United Kingdom (1), and Colombia (1).

Participant flow — Overall Study
MilestoneHydrus Microstent
Started100
Completed100
Not completed0

Outcome measures

PrimaryPercentage of Subjects With Greater Than or Equal to a 20 Percent Decrease From Baseline in Mean Diurnal Intraocular Pressure (MDIOP) at Month 12 While Maintaining the Same or Fewer Number of Medications as at Baseline

Intraocular pressure was measured using Goldmann Applanation tonometry. Three separate IOP measurements were taken over an 8-hour period and averaged together to achieve mean diurnal intraocular pressure.

Time frame:
Baseline, Month 12
Reported as:
Number · percentage of subjects
Percentage of Subjects With Greater Than or Equal to a 20 Percent Decrease From Baseline in Mean Diurnal Intraocular Pressure (MDIOP) at Month 12 While Maintaining the Same or Fewer Number of Medications as at Baseline
percentage of subjectsHydrus Microstent
Percentage of Subjects With Greater Than or Equal to a 20 Percent Decrease From Baseline in Mean Diurnal Intraocular Pressure (MDIOP) at Month 12 While Maintaining the Same or Fewer Number of Medications as at Baseline43.0
SecondaryMean Change From Baseline in MDIOP at Month 12

Intraocular pressure was measured using Goldmann Applanation tonometry and recorded in millimeters mercury (mmHG). Three separate IOP measurements were taken over an 8-hour period and averaged together to achieve mean diurnal intraocular pressure. A negative number represents a reduction from baseline. For non-responders, data was imputed as specified in the protocol. No hypothesis testing was pre-specified for this outcome measure.

Time frame:
Baseline, Month 12
Reported as:
Mean · mmHG
Mean Change From Baseline in MDIOP at Month 12
mmHGHydrus Microstent
Mean Change From Baseline in MDIOP at Month 12-3.77 ± 5.0

Adverse events

Collected over Adverse events were collected from the operative visit to study exit (approximately 12 months). AEs were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ocular Adverse Events0/100 (0%)5/100 (5%)55/100 (55%)
Non-Ocular Adverse Events0/100 (0%)0/100 (0%)0/100 (0%)
Most frequent serious events
Most frequent serious events
EventOcular Adverse EventsNon-Ocular Adverse Events
Worsening of visual fieldEye disorders3/1000/100
Elevated mean IOPEye disorders2/1000/100
Elevated IOPEye disorders1/1000/100
Most frequent other events
Most frequent other events
EventOcular Adverse EventsNon-Ocular Adverse Events
Worsening of visual fieldEye disorders19/1000/100
Elevated mean IOP at less than or equal to 1 month postoperativeEye disorders16/1000/100
BCVA loss at greater than 1 month postoperativeEye disorders15/1000/100
Surgical re-intervention in study eyeEye disorders15/1000/100
Elevated mean IOP at greater than 1 month postoperativeEye disorders14/1000/100
BCVA loss at less than or equal to 1 month postoperativeEye disorders10/1000/100
Device obstructionEye disorders10/1000/100
Hypotony (less than 6 mmHg)Eye disorders7/1000/100
AC cell or flare requiring change in steroid medication regimenEye disorders6/1000/100

Baseline characteristics

Safety Analysis Population

Age, Continuous
Age, Continuous(years)Hydrus Microstent
Mean71.3 ± 10.0
Age, Customized
Age, Customized(participants)Hydrus Microstent
Less than 60 years13
60 years to less than 70 years28
70 to less than 80 years35
80 years and greater24
Sex: Female, Male
Sex: Female, Male(Participants)Hydrus Microstent
Female52
Male48
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Hydrus Microstent
Asian7
Black or African American14
Mestizo2
White74
Refuses to Answer/Unknown3
08

Study locations

20 sites
  • Vold Vision
    Fayetteville, Arkansas 72704, United States
  • Sacramento Eye Consultants
    Sacramento, California 95815, United States
  • Eye Center of Northern Colorado
    Fort Collins, Colorado 80528, United States
  • Ocala Eye
    Ocala, Florida 34474, United States
  • Center for Sight
    Venice, Florida 34283, United States
  • Stiles Eyecare
    Overland Park, Kansas 66213, United States
  • Louisiana Eye and Laser Center
    Alexandria, Louisiana 71303, United States
  • Washington University in St. Louis Ophthalmology
    St Louis, Missouri 63110, United States
  • Scott & Christie and Associates
    Cranberry Township, Pennsylvania 16066, United States
  • Texan Eye
    Austin, Texas 78731, United States
  • Glaucoma Associates of Texas
    Dallas, Texas 75231, United States
  • El Paso Eye Surgeons
    El Paso, Texas 79902, United States
  • Ophthalmology Associates
    Fort Worth, Texas 76102, United States
  • Vale-Asche Russell Clinical Research Center
    Houston, Texas 77030, United States
  • R and R Research, LLC
    San Antonio, Texas 78229, United States
  • The Eye Centers of Racine and Kenosha
    Kenosha, Wisconsin 53142, United States
  • Clínica Oftalmológica
    Barranquilla, 080020, Colombia
  • Asian Eye Institute
    Makati City, 1200, Philippines
  • Hospital Universitario Miguel Servet
    Zaragoza, 50009, Spain
  • Manchester Royal Eye Hospital
    Manchester, M13 9WL, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2017 to primary completion in Dec 2022, 64 months.

Results were first posted in Jan 2026, 3 years after primary completion. A results delay was requested in Dec 2023.

Of 70 industry-sponsored interventional studies with no phase under Glaucoma, Open-Angle, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 64. This study's 64 months is above that.

Counting every sponsor, half of 171 studies reached it within 35 months; a quarter within 19 and three quarters within 61.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2017
First posted
Aug 30, 2017
StartActual
Aug 1, 2017
Primary completionActual
Dec 16, 2022
CompletionActual
Dec 16, 2022
Results delay requested
Dec 11, 2023
Results first posted
Jan 14, 2026
Last update
Jan 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03267134
Lead sponsor
Ivantis, Inc.
Responsible party
Sponsor
First posted
Aug 30, 2017
Start date
Aug 1, 2017
Primary completion
Dec 16, 2022
Completion
Dec 16, 2022
Results posted
Jan 14, 2026
Last update
Jan 14, 2026

Study contacts

Clinical Project Lead, CRD Surgical
study director · Alcon Research, LLC

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion